This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siegel, A. B. Articles by Schwartz, J. D. Search for Related Content PubMed PubMed Citation Articles by Siegel, A. B. Articles by Schwartz, J. D. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Liver Cancer Social Bookmarking                            What's this?

Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

Abby B. Siegel, Emil I. Cohen, Allyson Ocean, Deborah Lehrer, Alec Goldenberg, Jennifer J. Knox, Helen Chen, Sean Clark-Garvey, Alan Weinberg, John Mandeli, Paul Christos, Madhu Mazumdar, Elizabeta Popa, Robert S. Brown, Jr, Shahin Rafii, Jonathan D. Schwartz

From the Departments of Medicine and Surgery and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University; Mt. Sinai School of Medicine; Departments of Medicine and Public Health, Weill-Cornell Medical College; New York University Comprehensive Cancer Center, New York, NY; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Imclone Systems Incorporated, Branchburg, NJ; and Princess Margaret Hospital and Princess Margaret Phase II Consortium, Toronto, Ontario, Canada

Corresponding author: Abby B. Siegel, MD, Columbia University College of Physicians and Surgeons, 622 West 168th St, PH-14, New York, NY 10032-3784; e-mail: aas54{at}columbia.edu

Purpose To determine the clinical and biologic effects of bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC).

Patients and Methods Adults with organ-confined HCC, Eastern Cooperative Oncology Group performance status of 0 to 2, and compensated liver disease were eligible. Patients received bevacizumab 5 mg/kg (n = 12) or 10 mg/kg (n = 34) every 2 weeks until disease progression or treatment-limiting toxicity. The primary objective was to determine whether bevacizumab improved the 6-month progression-free survival (PFS) rate from 40% to 60%. Secondary end points included determining the effects of bevacizumab on arterial enhancement and on plasma cytokine levels and the capacity of patients' plasma to support angiogenesis via an in vitro assay.

Results The study included 46 patients, of whom six had objective responses (13%; 95% CI, 3% to 23%), and 65% were progression free at 6 months. Median PFS time was 6.9 months (95% CI, 6.5 to 9.1 months); overall survival rate was 53% at 1 year, 28% at 2 years, and 23% at 3 years. Grade 3 to 4 adverse events included hypertension (15%) and thrombosis (6%, including 4% with arterial thrombosis). Grade 3 or higher hemorrhage occurred in 11% of patients, including one fatal variceal bleed. Bevacizumab was associated with significant reductions in tumor enhancement by dynamic contrast-enhanced magnetic resonance imaging and reductions in circulating VEGF-A and stromal-derived factor-1 levels. Functional angiogenic activity was associated with VEGF-A levels in patient plasma.

Conclusion We observed significant clinical and biologic activity for bevacizumab in nonmetastatic HCC and achieved the primary study end point. Serious bleeding complications occurred in 11% of patients. Further evaluation is warranted in carefully selected patients.

Supported in part by a contract from the Department of Health and Human Services and the National Institutes of Health (NIH) to the New York Cancer Consortium an NIH Grant No. UL1 RR024156, a Pardes Scholarship and the Family and Friends of Steven Levinson (A.B.S.), and an NIH K23 award (Grant No. CA-90584; J.D.S.).

Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA.

This article is dedicated to the memory of Dr. Scott Wadler, physician, scientist, mentor, friend, and founder of the New York Phase II Consortium.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y.-Q. Xiong, H.-C. Sun, W. Zhang, X.-D. Zhu, P.-Y. Zhuang, J.-B. Zhang, L. Wang, W.-z. Wu, L.-X. Qin, and Z.-Y. Tang Human Hepatocellular Carcinoma Tumor-derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells Clin. Cancer Res., August 1, 2009; 15(15): 4838 - 4846. [Abstract] [Full Text] [PDF]

				S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George Understanding and managing the possible adverse effects associated with bevacizumab Am. J. Health Syst. Pharm., June 1, 2009; 66(11): 999 - 1013. [Abstract] [Full Text] [PDF]

				J. M. Llovet and J. Bruix Testing Molecular Therapies in Hepatocellular Carcinoma: The Need for Randomized Phase II Trials J. Clin. Oncol., February 20, 2009; 27(6): 833 - 835. [Full Text] [PDF]